Transcenta Announces the Appointment of Daniel Weng as Chief Financial Officer
SUJOU, China, December 16, 2021 / PRNewswire / – Transcenta Holding Limited (“Transcenta”) (HKEX: 06628), a clinical-stage biopharmaceutical company with fully integrated capabilities in the discovery, research, development and manufacture of antibody-based therapeutics, announces the appointment of Daniel Weng as chief financial officer of the company, reporting to Xueming Qian, CEO. As a member of the management team, Daniel will be fully responsible for the company’s financial strategy, performance reporting, capital markets activities and investor relations, helping the company to make a Leap Forward.
Prior to joining Transcenta, he was Vice President and Chief Financial Officer at CStone Pharmaceuticals, a HKEX listed company, and has overall responsibility for the finance functions, where he made significant contributions to the business strategy leading to a commercial launch. succeeded in China and Taiwan as well as the prioritization of research and development. Prior to CStone Pharmaceuticals, he was Vice President and Chief Financial Officer at Everest Medicines, a HKEX listed company. He led the entire IPO team and partnered with high growth investment banks for the preparation of the IPO and achieved a successful listing. Prior to that, Daniel served as CFO of China at Amgen. He was responsible for all of the financial operations of China related to commercial operations, research and development activities, business development and strategic collaborations. Prior to Amgen, Daniel spent nearly 15 years as a senior and executive finance professional at multinational companies such as GE, Honeywell in China and overseas.
Daniel holds a master’s degree in University of Sydney in finance and accounting in Australia. He is an Australian CPA and a member of ACCA.
âWe are delighted with the arrival of Daniel. Its membership will further strengthen our leadership team,” said dr. Xueming Qian, CEO of Transcenta. “Daniel brings with over 23 years of solid experience in all finance functions with exposures in both biotechnology and multinationals, and he is a seasoned leader with exceptional experience in financial operations and capital markets in several public companies. I look forward to working with Daniel to grow and take the business to the next level. “
âTranscenta is focused on the development of therapeutic antibody molecules for oncology and certain non-oncology indications, including bone and kidney disorders, and is dedicated to the development of first-order and first-order biologics. As a fully integrated international biopharmaceutical company, Transcenta has also built an experienced and knowledgeable management team.I am honored to join this excellent team at such an exciting time, I hope my financial expertise, management experience and my extensive network in the biopharmaceutical industry will advance the sustainable development of the company in capital markets and drive its value.” noted Daniel.
About Transcenta Holding Limited
Transcenta (HKEX: 06628) is a clinical-stage biopharmaceutical company with fully integrated capabilities in the discovery, research, development and manufacture of antibody-based biotherapeutics.
Transcenta has established a global presence, with a corporate headquarters and clinical and translational research center in Suzhou, a process and product development center, and a manufacturing facility in Hangzhou, and clinical development centers in Beijing, Shanghai and Canton in China and in Princeton, United States and External Partnership Center at Boston and Los Angeles, WE. Transcenta is developing nine therapeutic antibody molecules for oncology and certain non-oncological indications, including bone and kidney disorders.
This press release may contain certain forward-looking statements which are, by their nature, subject to important risks and uncertainties. The words âanticipateâ, âbelieveâ, âestimateâ, âexpectâ, âintendâ and similar expressions, with respect to Transcenta, are intended to identify certain of these forward-looking statements. Transcenta does not intend to regularly update these forward-looking statements.
These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Transcenta regarding future events at the time these statements are made. These statements are not guarantees of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Transcenta’s control and are difficult to predict. Therefore, actual results may differ materially from information contained in forward-looking statements due to future changes or developments in our business, the competitive environment of Transcenta and political, economic, legal and social conditions.
Transcenta, the directors and employees of Transcenta assume (a) no obligation to correct or update any forward-looking statements contained in this site; and (b) no responsibility for the failure of any forward-looking statements to materialize or to prove to be inaccurate.
Public relations: [email protected]
Investor relations: [email protected]
Business development: [email protected]
SOURCE Transcenta Holding Limited
Company codes: Hong Kong: 6628